Moneycontrol PRO
you are here: HomeNewsBusiness

Buy Suven Pharmaceuticals; target of Rs 650: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 650 in its research report dated August 16, 2021.

August 19, 2021 / 01:31 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Suven Pharmaceuticals

Suven Pharma is a CDMO that supports global life sciences industry & fine chemical majors in their NCE development endeavours. Its services include custom synthesis, process R&D, scale-up & contract manufacturing. Business comprises three segments – CDMO (development projects and commercial supplies), specialty chemicals and contract technical service CDMO vertical contributes more than 62% of its topline. Owing to its CDMO competence, it has developed & supplies intermediates for two specialty chemical products (agrochemical) to large global conglomerates


We retain our BUY rating on this stock We value Suven at Rs 650 with 32x P/E on FY23E EPS

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 19, 2021 01:31 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark